Craig A. Johnson
Known title: DirectorCIK: 0001370348
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
Transaction History
| HRTX | ▲ Buy | Grant | 53,960 | $0 | 1/30/2026 | View on chart |
| AUPH | ▼ Sell | Tax Withholding | 6,039 | $95K | 11/21/2025 | View on chart |
| HRTX | ▲ Buy | Grant | 17,950 | $0 | 1/30/2025 | View on chart |
| AUPH | ▲ Buy | Grant | 20,631 | $0 | 11/21/2024 | View on chart |
| HRTX | ▲ Buy | Grant | 13,948 | $0 | 1/19/2024 | View on chart |
| HRTX | ▲ Buy | Grant | 38,580 | $0 | 12/16/2022 | View on chart |
| HRTX | ▲ Buy | Grant | 10,452 | $0 | 12/22/2021 | View on chart |
| HRTX | ▼ Sell | Open Market | 250 | $2K | 12/21/2021 | View on chart |
| HRTX | ▼ Sell | Open Market | 250 | $3K | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.